Cargando…
Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma
Immune checkpoint inhibitors (ICIs) have improved clinical outcomes with a number of advanced malignancies. However, diverse immune-related adverse events (iRAEs) occurred with the widespread use of ICIs, some of which are rarely and life-threatening. Here we report a 66-year-old patient with lung a...
Autores principales: | Xing, Qian, Zhang, Zhong-Wei, Lin, Qiong-Hua, Shen, Li-Hua, Wang, Peng-Mei, Zhang, Shan, Fan, Ming, Zhu, Biao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154453/ https://www.ncbi.nlm.nih.gov/pubmed/32309397 http://dx.doi.org/10.21037/atm.2020.01.79 |
Ejemplares similares
-
Myocarditis-myositis-myasthenia gravis overlap syndrome depending on immune checkpoint inhibitor
por: Ünlütürk, Zeynep, et al.
Publicado: (2023) -
Nivolumab-Induced Myasthenia Gravis Concomitant With Myocarditis, Myositis, and Hepatitis
por: Bawek, Sawyer J, et al.
Publicado: (2021) -
Immune checkpoint inhibitor sintilimab-induced lethal myocarditis overlapping with myasthenia gravis in thymoma patient: A case report
por: Wang, Chen, et al.
Publicado: (2023) -
Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report
por: Cham, Jason, et al.
Publicado: (2021) -
Mogamulizumab-Associated Myositis With and Without Myasthenia Gravis and/or Myocarditis in Patients With T-Cell Lymphoma
por: Virgen, Cesar A, et al.
Publicado: (2023)